An observational study in Asthma, sponsored by Johns Hopkins University. Completed at 1 site in United States. Open to participants aged 12 Years to 85 Years. Per ClinicalTrials.gov, last updated 2018-08-21.
Sponsored by Johns Hopkins University · Observational
The purpose of this study will be to assess the impact of a culturally-sensitive, patient-focused asthma communication instrument (ACCI) designed to enhance provider-patient communication by prompting and guiding providers in assessments of disease severity and discussion of adherence behaviors with minority patients with asthma.
Improving communication between health care providers and their patients is the critical first step in efforts designed to reduce asthma-related health disparities in urban areas. Improving communication will help providers tailor asthma therapies to their patients' needs, and help providers and patients to overcome barriers (e.g., concerns about adverse effects) to adherence with those asthma treatment plans.
3,921 studies on the registry are indexed under Asthma; 507 are open to participants now.
This study's planned enrollment of 350 is above the median of 150 across 970 observational studies indexed under Asthma.
Browse Asthma studies →Johns Hopkins University is the lead sponsor of 1,783 studies on the registry; 313 are open to participants now.
Of its 203 completed or terminated interventional studies of FDA-regulated products, 140 (69%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Accuracy of Provider Assessment of Asthma Severity
Accuracy of Clinician Assessment of Patient Adherence
Assessment of appropriateness of asthma treatment (consistency of care with asthma guidelines
Patient satisfaction with provider-patient communication and medical care
These outcomes include indicators of poor asthma control such as health care service use for asthma exacerbations (unscheduled office visits, ER visits, hospitalizations) and use of oral corticosteroid and overuse of inhaled beta-agonist medications.
This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Johns Hopkins University